Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4076 Following Multiple Ascending Dose Administration to T2DM Subjects With Non-Alcoholic Fatty Liver Disease

NCT02826525 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02826525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02826525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4076 Following Multiple Ascending Dose Administration to T2DM Subjects With Non-Alcoholic Fatty Liver Disease
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
July 18, 2016
Completion date
October 11, 2019
Enrollment
14 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

t2dm with nafld